Omalizumab, mepolizumab, reslizumab i benralizumab per al tractament de l’asma greu no controlada en pacients adults: informe d’avaluació de resultats
Asthma is a chronic inflammatory disease of an inflammatory nature involving immune system cells and immunomodulators, which cause an inflammatory response in the bronchi causing airflow obstruction. In Spain, the prevalence is estimated at 4.9% in adults. The goal of treatment is to achieve and maintain control of the disease, prevent exacerbations and chronic airflow obstruction, and reduce associated mortality. Pharmacological treatment of asthma is staggered and periodically reviewed with the goal that the patient is always monitored. Uncontrolled severe asthma (CNA) is defined as those cases that require treatment with high doses of inhaled corticosteroids (IC), plus a second control medication and / or the use of oral corticosteroids (CO) to prevent loss. of disease control. The prevalence of AGNC is estimated at 3.9% of asthmatics.
Uncontrolled severe asthma; Monoclonal antibodies; Health outcomes
Programa d'Harmonització Farmacoterapèutica. Omalizumab, mepolizumab, reslizumab i benralizumab per al tractament de l’asma greu no controlada en pacients adults: informe d’avaluació de resultats. Barcelona: Servei Català de la Salut; 2021.
Use this identifier for quote and/or link this documenthttp://hdl.handle.net/11351/6461
This item appears in following collections
The following license files are associated with this item: